Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Moorslede – page 115

2 287 clinical trials in Moorslede, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Moorslede at a glance
2 287
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 287 trials in Moorslede

Open in trial search

Breast cancer+1

Not recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Influenza

Not recruiting

Study of mRNA-based seasonal influenza vaccine to evaluate immune response and safety in adults 18 years and older

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:GSKVX000000034794
  • Sponsor:GlaxoSmithKline Biologicals

Study of zoldonrasib in patients with RAS G12D mutation non-small cell lung cancer who have received previous treatment

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Zoldonrasib
  • Sponsor:Revolution Medicines Inc.

Alopecia areata

Not recruiting

Study of ritlecitinib for treating severe alopecia areata in children aged 6 to under 12 years

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years
  • Sponsor:Pfizer Inc.

Colitis ulcerative

Not recruiting

Study of SAR442970 to treat moderate to severe ulcerative colitis in adults

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:SAR442970
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Retinitis pigmentosa

Not recruiting

Study of ultevursen treatment in patients with retinitis pigmentosa caused by mutations in USH2A gene exon 13

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ultevursen
  • Sponsor:Laboratoires Thea

Study of tarlatamab alone or with FOLFIRI chemotherapy for patients with advanced digestive system or unknown origin neuroendocrine carcinomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Grupo Espanol De Tumores Neuroendocrinos

Study of datopotamab deruxtecan with or without durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Amgen Inc.

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Adenocarcinoma gastric+3

Not recruiting

Study of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Moorslede

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) deprescribing strategies for patients with chronic usage patterns. This research evaluates different approaches to medication management for individuals with functional dyspepsia and reflux conditions.

  • PPI Deprescribing Methods
  • Gastrointestinal Health Management
  • Alternative Treatment Strategies

The research explores on-demand medication use and alternative therapeutic options, aiming to establish optimal treatment withdrawal protocols while maintaining patient comfort and health outcomes.

02 Digestive Health Studies

Clinical investigations centered on managing heartburn and related digestive conditions through innovative treatment approaches. The research examines the effectiveness of alginate-based alternatives and intermittent dosing strategies.

  • Medication Optimization
  • Alternative Therapies
  • Patient-Centered Approaches

This primary care research initiative aims to enhance treatment protocols for patients requiring long-term digestive health management.

03 Primary Care Innovation

Forward-thinking research in primary care settings exploring evidence-based approaches to medication management. The study compares traditional and innovative methods for reducing long-term medication dependency.

  • Clinical Practice Improvement
  • Patient Safety Protocols
  • Treatment Optimization

The research focuses on developing practical, patient-friendly approaches to medication reduction while maintaining therapeutic effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.